1-(4-(6-fluoropyridin-3-yl)phenyl)ethan-1-one | 1246092-16-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-(6-fluoropyridin-3-yl)phenyl)ethan-1-one
• 英文别名: 1-(4-(6-Fluoropyridin-3-yl)phenyl)ethanone；1-[4-(6-fluoropyridin-3-yl)phenyl]ethanone
• CAS: 1246092-16-9
• 化学式: C₁₃H₁₀FNO
• 分子量: 215.227
• InChiKey: NUAINRRNJQVXAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-(6-fluoropyridin-3-yl)phenyl)ethan-1-one 在 1-羟基苯并三唑 、 一水合肼 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 氯仿 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.25h， 生成 5-(5-(2-chloro-7-ethoxyquinolin-3-yl)-3-(4-(6-fluoropyridin-3-yl)phenyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(3-morpholinopropyl)-5-oxopentanamide
  参考文献：
  名称：

  Structure-Guided Optimization of Replication Protein A (RPA)–DNA Interaction Inhibitors

  摘要：

  Replication protein A (RPA) is the major human single stranded DNA (ssDNA)-binding protein, playing essential roles in DNA replication, repair, recombination, and DNA-damage response (DDR). Inhibition of RPA-DNA interactions represents a therapeutic strategy for cancer drug discovery and has great potential to provide single agent anticancer activity and to synergize with both common DNA damaging chemotherapeutics and newer targeted anticancer agents. In this letter, a new series of analogues based on our previously reported TDRL-551 (4) compound were designed to improve potency and physicochemical properties. Molecular docking studies guided molecular insights, and further SAR exploration led to the identification of a series of novel compounds with low micromolar RPA inhibitory activity, increased solubility, and excellent cellular up-take. Among a series of analogues, compounds 43, 44, 45, and 46 hold promise for further development of novel anticancer agents.

  DOI：

  10.1021/acsmedchemlett.9b00440
• 作为产物：
  描述：

  4-碘代苯乙酮 、 2-氟-5-吡啶硼酸 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 水 、 甲苯 为溶剂， 反应 18.0h， 以90%的产率得到1-(4-(6-fluoropyridin-3-yl)phenyl)ethan-1-one
  参考文献：
  名称：

  Structure-Guided Optimization of Replication Protein A (RPA)–DNA Interaction Inhibitors

  摘要：

  Replication protein A (RPA) is the major human single stranded DNA (ssDNA)-binding protein, playing essential roles in DNA replication, repair, recombination, and DNA-damage response (DDR). Inhibition of RPA-DNA interactions represents a therapeutic strategy for cancer drug discovery and has great potential to provide single agent anticancer activity and to synergize with both common DNA damaging chemotherapeutics and newer targeted anticancer agents. In this letter, a new series of analogues based on our previously reported TDRL-551 (4) compound were designed to improve potency and physicochemical properties. Molecular docking studies guided molecular insights, and further SAR exploration led to the identification of a series of novel compounds with low micromolar RPA inhibitory activity, increased solubility, and excellent cellular up-take. Among a series of analogues, compounds 43, 44, 45, and 46 hold promise for further development of novel anticancer agents.

  DOI：

  10.1021/acsmedchemlett.9b00440

文献信息

• Imaging agents for detecting neurological disorders
  申请人：Gangadharmath Umesh B.

  公开号：US20100239496A1

  公开（公告）日：2010-09-23

  Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

  本文提供了一种公式（I）的成像剂和检测神经系统疾病的方法，包括向需要的患者施用能够结合tau蛋白和β-淀粉样肽的公式（I）化合物。该发明还涉及成像Aβ和tau聚集物的方法，包括引入含有公式（I）放射标记化合物的制剂的可检测量，并检测与淀粉样沉积物和/或tau蛋白相关的标记化合物在患者体内的情况。这些方法和组合物使得能够进行临床前诊断和监测阿尔茨海默病和其他神经系统疾病的进展。
• [EN] REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS<br/>[FR] INHIBITEURS DE L'INTERACTION PROTÉINE A DE RÉPLICATION (RPA)-ADN
  申请人：UNIV INDIANA TRUSTEES

  公开号：WO2021119242A1

  公开（公告）日：2021-06-17

  This invention relates to RPA compounds or pharmaceutically acceptable salts thereof, and for the use of the compounds to treat cancer.

  这项发明涉及RPA化合物或其药用盐，以及利用这些化合物治疗癌症的用途。
• 一种三氮唑醇芳杂环醚类衍生物及其制备方 法和应用
  申请人：上海倚诺升生物医药科技有限公司

  公开号：CN105237513B

  公开（公告）日：2018-01-23

  本发明涉及一种三氮唑醇芳杂环醚类衍生物及其制备方法和应用，具体提供了所述的三氮唑醇芳杂环醚类衍生物的结构通式，制备方法，其晶型、药学上可接受的无机酸盐或有机酸盐、水合物、溶剂合物或前药，以及用途。通过体外和体内抑菌实验证实本发明合成的化合物对人体致病真菌白色念珠菌、近平滑念珠菌、新生隐球菌、光滑假丝酵母菌、烟曲霉菌、石膏状小孢子菌、红色毛癣菌具有显著的抑制活性，优于氟康唑，而且该化合物还具有毒性低、抗真菌谱广等优点，因此可用于制备抗真菌药物。
• Imaging Agents for Detecting Neurological Disorders
  申请人：Szardenings Anna Katrin

  公开号：US20110182812A1

  公开（公告）日：2011-07-28

  Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

  本文介绍了公式（I）-（V）的成像剂和用于检测神经系统疾病的方法，其中包括向需要治疗的患者注射能够结合tau蛋白和β-淀粉样肽的公式（I）-（V）化合物。本发明还涉及成像Aβ和tau聚集物的方法，包括引入含有放射性标记的公式（I）-（V）化合物的制剂，并检测与淀粉样沉积物和/或tau蛋白相关联的标记化合物。这些方法和组合物可用于预临床诊断和监测AD和其他神经系统疾病的进展。
• IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS
  申请人：Siemens Medical Solutions USA, Inc.

  公开号：EP2411057A2

  公开（公告）日：2012-02-01